Search clinical trials for: EUR-1008 (APT-1008) High Dose

Total 249 results

Forest Laboratories

Completed

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Chronic Pancreatitis | Exocrine Pancreatic Insufficiency

United States, Italy, Ukraine
Forest Laboratories

Completed

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany
Forest Laboratories

Completed

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

PR-018: An Open-Label, Safety Extension of Study PR-011

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Israel Institute for Biological Research (IIBR)

Completed

Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

Covid19

Israel
Curacle Co., Ltd.
KCRN Research, LLC

Completed

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Diabetic Macular Edema

United States
Charleston Laboratories, Inc

Completed

A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route

Pain | Nausea | Vomiting
Ohio State University Comprehensive Cancer Center
Varian Medical Systems

Active, not recruiting

Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia (PREVENT)

Pneumonia | Covid-19 | Sars-CoV2

United States, Colombia
Sound Pharmaceuticals, Incorporated
Medical University of South Carolina; Cystic Fibrosis Foundation

Enrolling by invitation

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

Ototoxicity

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Muscular Dystrophy | Limb Girdle Muscular Dystrophy | LGMD2I | LGMD | Limb-Girdle Muscular Dystrophy Type 2 | LGMD2 | FKRP | FKRP Mutation | Fukutin Related Protein

United States
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin

Healthy
Forest Laboratories

Completed

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Exocrine Pancreatic Insufficiency: Cystic Fibrosis

United Kingdom, Italy, Belgium, Bulgaria, France, Germany, Poland
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
Ariston Pharmaceuticals, Inc.

Unknown

Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

Migraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With Aura

Finland, Netherlands, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
Axter Therapeutics (Beijing) Co., Ltd

Recruiting

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed or Refractory Non-Hodgkin's Lymphoma

China
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
Boehringer Ingelheim

Completed

Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers

Healthy
Dow Pharmaceutical Sciences

Completed

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis

Onychomycosis

Mexico
Pierre Fabre Pharma AG

Completed

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). (Real-CHOICE)

Iron-Deficiency Anemia | Iron-Deficiency

Switzerland
Ente Ospedaliero Ospedali Galliera

Active, not recruiting

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Iron Overload | Neurodegenerative Disease

Italy
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Juventas Therapeutics, Inc.

Unknown

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure (RETRO-HF)

Ischemic Heart Failure

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239

Healthy

Portugal
Juventas Therapeutics, Inc.

Unknown

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure. (STOP-HF)

Ischemic Heart Failure

United States
Exicure, Inc.

Completed

A Study of AST-008 in Healthy Subjects

Healthy Volunteer Study

United Kingdom
Boryung Biopharma Co., Ltd.

Completed

To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children

Tetanus | Diphtheria

Korea, Republic of
Adamis Pharmaceuticals Corporation

Unknown

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Prostate Cancer

United States
Aqualung Therapeutics Corp.

Not yet recruiting

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

Acute Respiratory Distress Syndrome (ARDS)
OliPass Corporation

Completed

OLP-1002 is Being Studied in the Treatment of Pain.

Pain

United Kingdom
Pfizer

Completed

Glasdegib Renal Impairment Study

Renal Impairment

United States
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

Healthy

Korea, Republic of
Leiden University Medical Center
Dutch Colorectal Cancer Group; Stichting Darmkanker

Not yet recruiting

DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients With Metastatic Colorectal Cancer (DOSAGE)

Colorectal Cancer | Metastatic Cancer | Older Patients | Candidates for Palliative Chemotherapy

Netherlands
Sprout Pharmaceuticals, Inc

Completed

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Sexual Dysfunctions, Psychological

United States
Boehringer Ingelheim

Completed

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Healthy
Pfizer

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

Hepatic Impairment

United States
Galapagos NV

Completed

Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects

Healthy

United Kingdom
Aqualung Therapeutics Corp.

Completed

First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100

ARDS, Human

Australia
Bausch Health Americas, Inc.

Completed

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

Sickle Cell Disease

United States, Canada, Kenya
Mbarara University of Science and Technology
The Hospital for Sick Children

Unknown

Development of a Mobile Application for HBB Prompt Study (HBB-Prompt)

Neonatal Death | Birth Asphyxia

Uganda
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

Influenza

China
Meir Medical Center

Completed

Use of APX 100 Device for Small-pupil Cataract Surgery and Intraoperative Floppy-iris Syndrome

Intraoperative Floppy Iris Syndrome | Miosis Disorder

Israel
Wenzhou Medical University

Active, not recruiting

Repeatability and Reproducibility of Lens Zonule Length Measurement Using ArcScan Insight 100

Zonule of Zinn Abnormality | Zonular Cataract

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
National Taiwan University Hospital
Mrs. Hsiu-Chin Lee Kidney Research Fund

Unknown

High Flux Hemodialysis Thrice Versus Once

End-Stage Renal Disease

Taiwan
Sound Pharmaceuticals, Incorporated
University of Florida

Completed

Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Temporary Auditory Threshold Shift

United States

3

Subscribe